Literature DB >> 19374596

New TNM classification for non-small-cell lung cancer.

Lynn T Tanoue1, Frank C Detterbeck.   

Abstract

The International Association for the Study of Lung Cancer (IASLC) staging committee has recently completed a decade of work devoted to updating the stage classification system for lung cancer. The IASLC has proposed revisions based on the evaluation of outcomes in an extensive worldwide database. This review outlines the changes in the tumor, node, metastasis (TNM) descriptors and stage groupings anticipated in the official new stage classification system for non-small-cell lung cancer with the forthcoming publication of the 7th Edition of the stage classification.

Entities:  

Mesh：

Year:  2009        PMID： 19374596     DOI： 10.1586/era.09.11

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  32 in total

1.  What are the True Advantages of Devices for Hepatic Parenchymal Transection in Open Surgery? Reply.

Authors:  Naoto Gotohda; Takeharu Yamanaka; Akio Saiura; Katsuhiko Uesaka; Masaji Hashimoto; Masaru Konishi; Kazuaki Shimada
Journal:  World J Surg       Date:  2015-12       Impact factor: 3.352

2.  Selection for adjuvant chemotherapy in completely resected stage I non-small cell lung cancer: external validation of a Chinese prognostic risk model.

Authors:  Ulas Kumbasar; Hilgardt Raubenheimer; May Al Sahaf; Nizar Asadi; Maria Elena Cufari; Chiara Proli; Periklis Perikleous; Zakiyah Niwaz; Emma Beddow; Vladimir Anikin; Niall McGonigle; Simon Jordan; George Ladas; Michael Dusmet; Eric Lim
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

3.  Sub-cutaneous Fat Mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab.

Authors:  Geoffrey Popinat; Stéphanie Cousse; Lucas Goldfarb; Stéphanie Becker; Isabelle Gardin; Mathieu Salaün; Sébastien Thureau; Pierre Vera; Florian Guisier; Pierre Decazes
Journal:  Oncoimmunology       Date:  2019-03-06       Impact factor: 8.110

Review 4.  Lung cancer: Biology and treatment options.

Authors:  Hassan Lemjabbar-Alaoui; Omer Ui Hassan; Yi-Wei Yang; Petra Buchanan
Journal:  Biochim Biophys Acta       Date:  2015-08-19

5.  Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy.

Authors:  R Li; Q Li; S Lin; W Li; L Yu; L Wang; X Dong; L Yu; S Li; W Liu; B Li
Journal:  Clin Transl Oncol       Date:  2018-07-18       Impact factor: 3.405

6.  Large cell neuroendocrine carcinoma: topic review and a unique case of metastasis to the mandible.

Authors:  Keith M Schneider; Alan Y Martinez; Marcello Guglielmi
Journal:  J Maxillofac Oral Surg       Date:  2012-04-29

7.  Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5'-methylthioadenosine phosphorylase.

Authors:  Indranil Basu; Joseph Locker; Maria B Cassera; Thomas J Belbin; Emilio F Merino; Xinyuan Dong; Ivan Hemeon; Gary B Evans; Chandan Guha; Vern L Schramm
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

8.  Decreased expression of Beclin-1 and LC3 in human lung cancer.

Authors:  Zi-Feng Jiang; Li-Jie Shao; Wei-Min Wang; Xue-Bo Yan; Rong-Yu Liu
Journal:  Mol Biol Rep       Date:  2011-05-10       Impact factor: 2.316

9.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.

Authors:  Ramón Rami-Porta; Hisao Asamura; Peter Goldstraw
Journal:  Transl Lung Cancer Res       Date:  2015-08

10.  Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population.

Authors:  Christopher T Erb; Kevin W Su; Pamela R Soulos; Lynn T Tanoue; Cary P Gross
Journal:  Lung Cancer       Date:  2016-07-19       Impact factor: 5.705
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.